Published in
American Society of Hematology, Blood Advances, 20(3), p. 2920-2933, 2019
DOI: 10.1182/bloodadvances.2019000350
Links
Tools
Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1–derived peptides overcomes drug resistance
Journal article published in 2019 by
Elodie Pramil,
Linda Herbi Bastian,
Thomas Denèfle 
,
Fariba Nemati,
Malina Xiao,
Eva Lardé,
Karim Maloum ,
Damien Roos-Weil ,
Elise Chapiro ,
Magali Le Garff-Tavernier ,
Frédéric Davi,
Didier Decaudin,
Marika Sarfati ,
Florence Nguyen-Khac ,
Hélène Merle-Béral
and other authors.
,
Fariba Nemati,
Malina Xiao,
Eva Lardé,
Karim Maloum ,
Damien Roos-Weil ,
Elise Chapiro ,
Magali Le Garff-Tavernier ,
Frédéric Davi,
Didier Decaudin,
Marika Sarfati ,
Florence Nguyen-Khac ,
Hélène Merle-Béral
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Key PointsN-methylated thrombospondin-1 mimetic peptides selectively kill the leukemic CD5+ B cells, sparing mature and precursor nontumor cells. CD47 peptide triggering eliminates drug-resistant CLL cells by inducing an original form of cell death regulated by G proteins.